<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/"><channel rdf:about="http://www.journalofclinicalvirology.com//inpress?rss=yes"><title>Journal of Clinical Virology - Articles in Press</title><description>Journal of Clinical Virology RSS feed: Articles in Press. 
 Journal of Clinical Virology  is an international journal publishing papers on any aspect of human virology that directly pertains 
to virus-induced clinical conditions under the major headings of: Epidemiology, Pathogenesis, Diagnosis and Detection, and Prevention 
and Treatment. Articles from any field of virological study will be considered if the article is relevant to the understanding or manipulation 
of a disease state.</description><link>http://www.journalofclinicalvirology.com//inpress?rss=yes</link><dc:publisher>Elsevier Inc.</dc:publisher><dc:language>en</dc:language><dc:rights> © 2010 Elsevier B.V. All rights reserved. </dc:rights><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:issn>1386-6532</prism:issn><prism:publicationDate>2010-03-08</prism:publicationDate><prism:copyright> © 2010 Elsevier B.V. All rights reserved. </prism:copyright><prism:rightsAgent>healthpermissions@elsevier.com</prism:rightsAgent><items><rdf:Seq><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000387/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000521/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000570/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000582/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000533/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000508/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000120/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000156/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000235/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS138665321000051X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000259/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS138665321000020X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000211/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000223/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000247/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000144/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000193/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000132/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS138665321000017X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000181/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000028/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653210000168/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653209005952/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653209005460/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journalofclinicalvirology.com/article/PIIS1386653209002315/abstract?rss=yes"/></rdf:Seq></items></channel><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000387/abstract?rss=yes"><title>Survey for the presence of BK, JC, KI, WU and Merkel cell polyomaviruses in human brain tissues - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000387/abstract?rss=yes</link><description>Abstract: Background: Recently three previously unknown polyomaviruses (KI, WU and Merkel cell polyomaviruses) have been identified from human specimens. The spectrum of clinical manifestations and their tissue tropism are currently unknown. Since a member of this virus family, JC virus, is well-known for its capacity to establish latency in human brain tissue where reactivation in immunocompromised individuals can result in fatal progressive multifocal leukoencephalopathy, we sought to examine for the presence of all the five known human polyomaviruses in a series of human brain tissues.Objectives: To investigate the possibility of neuropersistence of the newly identified human polyomaviruses.Study design: Autopsy brain tissues were collected from 10 different brain regions of 30 individuals who died from diseases unrelated to viral infections. Nested PCR was used to assess the presence or absence of viral DNA.Results: Ten samples collected from five individuals were found to harbour JCV DNA. In contrast, none of the 300 brain tissues examined showed positive results for BK, KI, WU or Merkel cell polyomavirus.Conclusion: The newly identified KI, WU and Merkel cell polyomaviruses either do not, or have a much lower neuropersistent potential compared to JCV.</description><dc:title>Survey for the presence of BK, JC, KI, WU and Merkel cell polyomaviruses in human brain tissues - Corrected Proof</dc:title><dc:creator>W.Y. Lam, B.W. Leung, Ida M.T. Chu, Alexander C.L. Chan, H.K. Ng, Paul K.S. Chan</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.017</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-03-08</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-03-08</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000521/abstract?rss=yes"><title>Human Vaccinia virus and Pseudocowpox virus co-infection: Clinical description and phylogenetic characterization - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000521/abstract?rss=yes</link><description>Abstract: Background: Occupational exanthematic diseases represent an important cause of public health impact and economical losses. Among the viral exanthematic diseases, two caused by poxviruses are noteworthy: the bovine vaccinia (BV), caused by the Vaccinia virus (VACV); and the milker's nodule, in which the agent is the Pseudocowpox virus (PCPV). Both agents are zoonotic and have been associated with several cases of bovine infection. In Brazilian rural areas BV has been highly prevalent, particularly in milk herds. Farmers, milkers and their close contacts developed lesions on the hands, forearms, legs and face accompanied by several systemic symptoms. Although VACV and PCPV present with similar epidemiological and transmission patterns, no VACV and PCPV co-infection cases have to date been described.Objectives: To describe the first case of zoonotic VACV and PCVP co-infection, based on serological and molecular methods.Study design and results: In this work we report a case of a Brazilian rural worker who presented with a large severely ulcerated-pustule skin lesion, associated with fever, headache, malaise, myalgia and axillary, inguinal and cervical limphadenopathy. The worker declared occupational contact with cattle that had notable injuries on their teats. Human and bovine clinical samples were collected and submitted to serological and molecular tests. PCR and phylogenetic analysis revealed the presence of VACV DNA and PCPV DNA in the patient's lesion. Serological tests indicated anti-VACV neutralizing antibodies and molecular assays showed the presence of VACV and PCPV DNA in the patient sera. VACV and PCPV also were detected in dairy cattle.Conclusion: Together, these results indicate a case of zoonotic VACV/PCPV co-infection. Epidemiological surveillance and appropriate medical treatment are essential for the control of both diseases, especially in the most severe cases, as described in the present study.</description><dc:title>Human Vaccinia virus and Pseudocowpox virus co-infection: Clinical description and phylogenetic characterization - Corrected Proof</dc:title><dc:creator>Jônatas S. Abrahão, André T. Silva-Fernandes, Felipe L. Assis, Maria I. Guedes, Betânia P. Drumond, Juliana A. Leite, Luiz F.L. Coelho, Filippo Turrini, Flávio G. Fonseca, Zélia I.P. Lobato, Marieta Madureira, Paulo C. Ferreira, Cláudio A. Bonjardim, Giliane S. Trindade, Erna G. Kroon</dc:creator><dc:identifier>10.1016/j.jcv.2010.02.001</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-03-08</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-03-08</prism:publicationDate><prism:section>CASE REPORT</prism:section></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000570/abstract?rss=yes"><title>Early diagnosis of human immunodeficiency virus-1 infection in infants with the NucliSens EasyQ assay on dried blood spots - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000570/abstract?rss=yes</link><description>Abstract: Background: More routine laboratories in South Africa are equipped to perform quantitative than qualitative HIV viral detection assays. The accessibility of early infant diagnosis would be improved if a quantitative viral load (VL) assay performed on dried blood spots (DBS) could accurately diagnose HIV-infection. The VL assay routinely used in the country has not previously been assessed on DBS for early infant diagnosis.Objectives: To determine the accuracy of the NucliSens EasyQ assay (bioMerieux, Lyon, France) on DBS for early infant diagnosis of HIV in a subtype C-infected population.Study design: Stored DBS samples collected from children presenting for HIV testing were analyzed. DBS EasyQ VL results were compared to the child's HIV status as determined by a whole blood HIV DNA PCR result.Results: The EasyQ assay was performed on 235 stored DBS samples from 71 HIV-infected and 164 HIV-uninfected children. Of the 216 infants (children aged 12 months or less) tested, all 52 HIV-infected infants were detected (sensitivity of 100%). Six of 164 HIV-uninfected infants yielded false positive results (specificity 96.3%). All false positive and six of the true positive infants had VL&lt;3.7logIU/ml. These 12 (5.6%) infants would require repeat testing to differentiate true from false positives. Using a threshold above 3.7logIU/ml (equivalent to 4logcopies/ml) to define a positive result would yield an accurate diagnosis in 204 (94.4%) infants.Conclusions: DBS EasyQ VL assays provide an accurate option for early infant diagnosis in low resource settings.</description><dc:title>Early diagnosis of human immunodeficiency virus-1 infection in infants with the NucliSens EasyQ assay on dried blood spots - Corrected Proof</dc:title><dc:creator>R.R. Lilian, K. Bhowan, G.G. Sherman</dc:creator><dc:identifier>10.1016/j.jcv.2010.02.006</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-03-08</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-03-08</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000582/abstract?rss=yes"><title>Diagnostic assays for active infection with human herpesvirus 6 (HHV-6) - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000582/abstract?rss=yes</link><description>Abstract: Background: Human herpesvirus 6 (HHV-6) causes ubiquitous infection in early childhood with lifelong latency or persistence. Reactivation of HHV-6 has been associated with multiple diseases including encephalitis. Chromosomal integration of HHV-6 also occurs. Previous studies have suggested that the detection of HHV-6 DNA in plasma is an accurate marker of active viral replication.Objective: We sought to determine whether PCR assays on plasma could correctly differentiate between primary HHV-6 infection, chromosomal integration of HHV-6 and latent HHV-6 infection.Study design: We performed qualitative PCR, real-time quantitative PCR (RQ-PCR), and reverse-transcriptase PCR (RT-PCR) assays on samples of peripheral and cord blood mononuclear cells, as well as plasma, from groups of subjects with well defined HHV-6 infection, including subjects with chromosomally integrated HHV-6.Results and conclusions: The detection of HHV-6 DNA in plasma was 92% sensitive compared to viral isolation for the identification of primary infection with HHV-6. All plasma samples from infants with chromosomally integrated HHV-6 had HHV-6 DNA detectable in plasma while only 5.6% were positive by RT-PCR. The specificity of plasma PCR for active replication of HHV-6 was 84% compared to viral culture while the specificity of RT-PCR was 98%. Our results demonstrate that qualitative or quantitative PCR of plasma is insufficient to distinguish between active viral replication and chromosomal integration with HHV-6. We found a higher specificity of RT-PCR performed on PBMC samples compared to PCR or RQ-PCR performed on plasma when evaluating samples for active HHV-6 replication.</description><dc:title>Diagnostic assays for active infection with human herpesvirus 6 (HHV-6) - Corrected Proof</dc:title><dc:creator>Mary T. Caserta, Caroline Breese Hall, Kenneth Schnabel, Geraldine Lofthus, Andrea Marino, Lynne Shelley, Christina Yoo, Jennifer Carnahan, Linda Anderson, Hongyue Wang</dc:creator><dc:identifier>10.1016/j.jcv.2010.02.007</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-03-08</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-03-08</prism:publicationDate><prism:section>SHORT COMMUNICATION</prism:section></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000533/abstract?rss=yes"><title>Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000533/abstract?rss=yes</link><description>Abstract: Background: A nationwide outbreak of hand, foot and mouth disease (HFMD) occurred in Finland in autumn 2008. The outbreak was untypical since a considerable number of clinically diagnosed patients were adults. Furthermore, many of the patients suffered from onychomadesis several weeks after the acute phase of HFMD.Objectives: Detection, identification and phylogenetic analysis of human enteroviruses (HEV) that caused the outbreak.Study design: A total of 420 clinical specimens were obtained from 317 HFMD cases all over the country. The presence of HEV in the specimens was analysed by virus isolation and/or direct real-time RT-PCR; selected HEV strains were further typed by molecular methods. The genetic similarities of HEV strains were assessed by phylogenetic analyses on partial VP1 sequences.Results: HEV were detected in 212 HFMD cases, including both children and adults, throughout Finland. Two HEV types, coxsackieviruses A6 (CV-A6) and A10 (CV-A10), were identified as the causative agents of the outbreak. One genetic variant of CV-A6 predominated, but, additionally, three other genetically distinct CV-A6 strains were found. All CV-A10 strains segregated into one genetic cluster distinct from previously reported CV-A10 sequences.Conclusions: The Finnish 2008 HFMD outbreak was caused by two infrequently detected, co-circulating, coxsackie A viruses. Our data suggest endemic circulation of both CV-A types in Northern Europe and that the outbreak was due to the emergence of new genetic variants of these viruses.</description><dc:title>Co-circulation of coxsackieviruses A6 and A10 in hand, foot and mouth disease outbreak in Finland - Corrected Proof</dc:title><dc:creator>Soile Blomqvist, Päivi Klemola, Svetlana Kaijalainen, Anja Paananen, Marja-Leena Simonen, Tytti Vuorinen, Merja Roivainen</dc:creator><dc:identifier>10.1016/j.jcv.2010.02.002</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-03-02</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-03-02</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000508/abstract?rss=yes"><title>Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000508/abstract?rss=yes</link><description>Abstract: Background: Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens have been extensively used for treatment of HIV infection in resource-limited settings. Treatment options after failing an initial regimen are limited because of cross-resistance of NNRTIs.Objective: To determine the factors associated with reduced response to etravirine among patients with virological failure.Study design: A retrospective study was conducted. We stratified patients into two groups by the total weighted scores of etravirine-resistance-associated mutations (ETV-RAMs), highest response (score 0–2, N=123) and intermediate and reduced response (score ≥2.5, N=61). Factors associated with a score of ≥2.5 were evaluated.Results: There were 184 patients with mean (SD) age of 42 (9) years old and 60% were males. Of all, 68% used NNRTI in the failing regimen and 51% used stavudine/lamivudine as a backbone. Common ETV-RAMs included Y181C (27%), G190A (17%), and K101E (10%). Higher proportion of K101E, K101P, Y181C, G190S, and M230L were found in patients with a score of ≥2.5 (p&lt;0.05, all). By univariate logistic regression, using protease inhibitor (OR 0.22, 95% CI 0.07–0.67), nevirapine (OR 10.56, 95% CI 4.04–27.74), and efavirenz (OR 2.91, 95% CI 1.01–2.51) in the current regimen were associated with a score of ≥2.5. By multiple logistic regression, only using nevirapine was associated with a score of ≥2.5 (OR 7.61, 95% CI 2.40–24.06).Conclusions: Using nevirapine in the failing regimen was associated with intermediate and reduced response to ETV. The recommendation of using nevirapine as a preferred NNRTI should be re-considered in resource-limited settings where efavirenz is accessible.</description><dc:title>Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting - Corrected Proof</dc:title><dc:creator>Sasisopin Kiertiburanakul, Surasak Wiboonchutikul, Chonlaphat Sukasem, Wasun Chantratita, Somnuek Sungkanuparph</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.018</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-26</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-26</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000120/abstract?rss=yes"><title>Disease burden of herpes zoster in Korea - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000120/abstract?rss=yes</link><description>Abstract: Background: The occurrence of herpes zoster can deteriorate the quality of life considerably, resulting in high disease burden. While Korea is assumed to have high disease burden of herpes zoster, there has been no researches analyzing this.Objectives: We performed this study to investigate the disease burden of herpes zoster in the Korean population as a whole.Study design: We used the database of the Health Insurance Review &amp; Assessment Service of Korea and analyzed the data of patients who had herpes zoster as a principal diagnosis during the period from 2003 to 2007. We investigated the annual prevalence, rate of clinical visits, rate of hospitalization, and the pattern of medical services use. The socioeconomic burden of herpes zoster was calculated by a conversion into cost.Results: Rates of clinic visits and hospitalizations due to herpes zoster during the 5-year period from 2003 to 2007 were 7.93–12.54 per 1000 population and 0.22–0.32 per 1000 population, respectively. Prevalence rates according to age increased sharply after 50 years and reached a peak at 70 years. The total socioeconomic cost of herpes zoster was $75.9–143.8 million per year, increasing every year by 14–20%.Conclusions: There is a heavy socioeconomic burden due to herpes zoster in Korea and indicate that appropriate policies need to be established to reduce this burden. Additional researches are also necessary to assess the safety, efficacy and cost-effectiveness of a herpes zoster vaccine in the Korean population.</description><dc:title>Disease burden of herpes zoster in Korea - Corrected Proof</dc:title><dc:creator>Won Suk Choi, Ji Yun Noh, Joong Yeon Huh, Yu Mi Jo, Jacob Lee, Joon Young Song, Woo Joo Kim, Hee Jin Cheong</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.003</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-25</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-25</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000156/abstract?rss=yes"><title>Febrile neutropenia in a HIV positive individual post-chemotherapy - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000156/abstract?rss=yes</link><description>A HIV positive 50-year-old male presented to hospital with a fever of 39°C 8 days after commencing his sixth cycle of CHOP chemotherapy for stage IV B plasmablastic lymphoma.   The lymphoma was diagnosed 4 months earlier when he presented with anaemia, weight loss and a peri-anal mass. A HIV test was positive, CD4 count was 18×106cells/L and HIV RNA 500,000copies/mL. Antiretrovirals (tenofovir, emtricitabine, darunavir and ritonavir) and antimicrobial prophylaxis (acyclovir 400mg BD, fluconazole 50mg OD, azithromycin 1250mg weekly and co-trimoxazole 960mg OD) were initiated prior to commencing cytotoxic chemotherapy. During the first five cycles he had several episodes of neutropenic sepsis, without microbiological diagnosis, treated empirically as per local guidelines.</description><dc:title>Febrile neutropenia in a HIV positive individual post-chemotherapy - Corrected Proof</dc:title><dc:creator>E. Ridha, H. Cookson, E. Devitt, M. Nelson</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.006</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-22</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-22</prism:publicationDate><prism:section>VIROLOGY QUESTION AND ANSWER SCHEME (VIROQAS)</prism:section></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000235/abstract?rss=yes"><title>Impact of extensive HIV-1 variability on molecular diagnosis in the Congo basin - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000235/abstract?rss=yes</link><description>Abstract: Background: Previous studies have shown a high HIV-1 genetic variability in the Republic of Congo. This can greatly influence the performance of molecular assays for HIV-1 diagnosis.Objectives: To define a reliable test for detection of HIV-1 DNA in this area.Study design: We compared a commercial nested PCR (C-PCR) assay and an in house nested PCR (H-PCR) assay for the detection of HIV-1 DNA in the first 30 seropositive pregnant women enrolled into the ongoing “Kento-Mwana” project, for the prevention of HIV mother-to-child transmission in the city of Pointe Noire, Republic of Congo, Africa. Sequencing and phylogenetic analysis of partial HIV-1 pol sequences were also performed.Results: C-PCR detected HIV-1 DNA in only 15/30 samples from seropositive women (50.0%), as opposed to 29/30 (96.6%) by H-PCR (P&lt;0.0001). Phylogenetic analysis and bootscanning showed that only 10 sequences could be assigned to known clades (seven pure subtypes and three circulating recombinant forms), whereas the other 20 sequences were unique recombinant forms.Conclusions: The great genetic variability of HIV-1 in this area strongly advises to for using molecular methods only after local validation to avoid false negative results.</description><dc:title>Impact of extensive HIV-1 variability on molecular diagnosis in the Congo basin - Corrected Proof</dc:title><dc:creator>Bianca Bruzzone, Agostina Ventura, Francesca Bisio, Franc A. Mayinda Mboungou, Landry M. Miguel, Francesco Saladini, Maurizio Zazzi, Giancarlo Icardi, Andrea De Maria, Claudio Viscoli</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.014</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-22</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-22</prism:publicationDate><prism:section>SHORT COMMUNICATION</prism:section></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS138665321000051X/abstract?rss=yes"><title>Microsatellite analysis of HSV-1 isolates: From oropharynx reactivation toward lung infection in patients undergoing mechanical ventilation - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS138665321000051X/abstract?rss=yes</link><description>Abstract: Background: According to recent reports, herpes simplex virus type 1 (HSV-1) induces bronchopneumonitis (BPn) in immunocompetent patients undergoing prolonged mechanical ventilation (MV), whose respiratory functions deteriorate with a poor outcome. HSV-1 BPn is associated with HSV symptomatic or symptomless reactivation in the oropharynx.Objectives: We sought to systematically and genetically characterize HSV-1 strains isolated from immunocompetent patients receiving prolonged MV and to characterize the genetic relationship of strains sequentially isolated from oropharyngeal samples (OPS) and broncho-alveolar liquids (BAL) to determine the natural course of HSV BPn.Study design: In this molecular epidemiological study, microsatellite technology was used to determine genetic relationships between 211 HSV-1 strains isolated from OPS and/or BAL from 106 patients receiving MV.Results: Microsatellite haplotypes of HSV-1 strains sequentially isolated from the same individual were identical, and HSV-1 isolates from the lung were genetically indistinguishable from strains isolated from the oral cavity. Each patient was characterized by their own HSV-1 microsatellite haplotype, and no nosocomial transmission of strains between patients was observed.Conclusion: Our results demonstrate that, in patients who receive MV, the HSV-1 pulmonary infection results from the reactivation of genetically related HSV-1 in the oropharynx, which progressively infects the lower respiratory tract.</description><dc:title>Microsatellite analysis of HSV-1 isolates: From oropharynx reactivation toward lung infection in patients undergoing mechanical ventilation - Corrected Proof</dc:title><dc:creator>C. Deback, C.E. Luyt, S. Lespinats, C. Depienne, D. Boutolleau, J. Chastre, H. Agut</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.019</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-22</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-22</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000259/abstract?rss=yes"><title>Pooling the wrong conclusion - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000259/abstract?rss=yes</link><description>I read with interest the proof-of-concept study by Woo et al. on the use of high-density resequencing microarray for the detection of viruses from bacterial culture-negative conjunctival swabs.</description><dc:title>Pooling the wrong conclusion - Corrected Proof</dc:title><dc:creator>Da-Dong Huang</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.016</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-18</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-18</prism:publicationDate><prism:section>LETTER TO THE EDITOR</prism:section></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS138665321000020X/abstract?rss=yes"><title>Emergence of a genomic variant of the recombinant 2k/1b strain during a mixed Hepatitis C infection: A case report - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS138665321000020X/abstract?rss=yes</link><description>Abstract: To date, few natural intergenotypic recombinant hepatitis C virus (HCV) strains have been characterized. A recombinant strain 2k/1b was detected for one HCV RNA-positive individual who had just completed therapy for HCV 3a genotype infection. In the present report, five serum samples collected over the pre- and post-treatment periods were used to investigate all the present HCV strains and the change over time of the infection pattern.Interestingly, the 2k/1b strain was already present during the genotype 3a infection and persisted during treatment. In the specimen collected three months post-treatment, two distinct strains, 2k/1b and type 1, were found and then one 2k/1b strain in the subsequent ones. A genomic variant of the HCV RF1_2k/1b strain was identified. It was part of a mixed HCV infection and persisted and re-emerge after eradication of the dominant subtype 3a. This case indicates that HCV co-infection screening after relapse should be an alternative to explain the lack of response to treatment and the necessity to carefully study the epidemic spreading of this recombinant strain.</description><dc:title>Emergence of a genomic variant of the recombinant 2k/1b strain during a mixed Hepatitis C infection: A case report - Corrected Proof</dc:title><dc:creator>Virginie Morel, Véronique Descamps, Catherine François, Carole Fournier, Etienne Brochot, Dominique Capron, Gilles Duverlie, Sandrine Castelain</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.011</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-15</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-15</prism:publicationDate><prism:section>CASE REPORT</prism:section></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000211/abstract?rss=yes"><title>Detection and characterization of human parechoviruses in archived cell cultures, in Hungary - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000211/abstract?rss=yes</link><description>Abstract: Background: Human parechoviruses (HPeV) belonging to the family Picornaviridae are widespread enteric pathogens and associated with various clinical symptoms in humans.Objectives: There is no report for detection of the circulating parechoviruses in Central Europe. The aim of this retrospective study was to detect and characterize human parechoviruses in cell cultures with “enterovirus”-like cytophatic effect (CPE) archived between 1990 and 2000, in Hungary.Study design: Fecal samples from children with symptoms of gastroenteritis under age of 10 were cultured as a previous routine diagnostic laboratory protocol for “enterovirus”. Cell cultures indicating CPE were archived and deeply chilled (−80°C) from minimum 2 individuals (2–12 patients) in each year. Specimens were tested retrospectively, in 2009, for HPeV by reverse transcription-PCR (RT-PCR) method using 5′UTR conserved primers. Specific primer pairs were designed to determine the complete nucleotide sequence of the structural region (VP0–VP3–VP1) of HPeV.Results: Nine (9.1%) of 66 archived samples were found to be HPeV-positive. Six (67%) samples were identified as HPeV1, 2 (22%) were HPeV4 and 1 could not be determined. Three HPeV1 clusters were identified according to the isolation date originated from years 1990/1991, 1992/1995 and 1998.Conclusions: This is the first detection of human parechoviruses in Central Europe. Detection and genetic characterization of HPeV in available historical samples infected with previously unidentifiable agents with “enterovirus-like” cytopathogenic effect help to understand the genetic diversity and evolution of these viruses.</description><dc:title>Detection and characterization of human parechoviruses in archived cell cultures, in Hungary - Corrected Proof</dc:title><dc:creator>Ákos Boros, Mária Új, Péter Pankovics, Gábor Reuter</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.012</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-15</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-15</prism:publicationDate><prism:section>SHORT COMMUNICATION</prism:section></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000223/abstract?rss=yes"><title>HIV-1 elite controllers: Beware of super-infections - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000223/abstract?rss=yes</link><description>Abstract: Super- and co-infection with HIV-1 are generally associated with accelerated disease progression. We report on the outcome of super-infection in two HIV-1 infected individuals previously known as elite controllers. Both presented an acute retroviral syndrome following super-infection and showed an immuno–virological progression thereafter. Host genotyping failed to reveal any of the currently recognized protective factors associated with slow disease progression. This report indicates that elite controllers should be informed of the risk of super-infection, and illustrates the complexity of mounting broad anti-HIV immunity.</description><dc:title>HIV-1 elite controllers: Beware of super-infections - Corrected Proof</dc:title><dc:creator>Olivier Clerc, Sara Colombo, Sabine Yerly, Amalio Telenti, Matthias Cavassini</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.013</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-15</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-15</prism:publicationDate><prism:section>CASE REPORT</prism:section></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000247/abstract?rss=yes"><title>Are hepatitis B virus “subgenotypes” defined accurately? - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000247/abstract?rss=yes</link><description>Abstract: Background: Recently, several novel hepatitis B virus (HBV) subgenotypes have been introduced that do not meet proper definition of “subgenotypes”. In particular for HBV genotype A, such novel subgenotypes have been reported.Objective: To comprehensively reanalyse all HBV subgenotypes A, and to propose a novel, consistent alternative for HBV classification.Study design: All HBV full-length genome subgenotypes A1–A6 were reanalysed using phylogenetic reconstruction and genetic distance calculation in order to study their evolutionary relationships.Results: Phylogenetic analysis based on the complete genome sequence of subgenotype A strains revealed four distinct clusters supported by high bootstrap values, whereas only the three groups A1, A2 and A6 could be assigned as subgenotypes. Previously introduced subgenotype A3, “tentative A4” and A5 clustered together in one main branch and were designated as “quasi-subgenotypes”. Also genetic distances failed to classify these three groups as definite subgenotypes. These results advocate for a new classification of HBV genotype A into subgenotype A1, A2, “quasi-subgenotype A3” and A4.Conclusion: Detailed phylogenetic analysis of the complete genome sequences demonstrates that some of available HBV genotype A strains may not be considered as definite “subgenotypes”. These strains, which are mainly of African origin, could be considered as “quasi-subgenotypes” which puts them in between the “clade” and “subgenotype” definition. Geographical origin may have a key role in further classification of HBV subgenotypes.</description><dc:title>Are hepatitis B virus “subgenotypes” defined accurately? - Corrected Proof</dc:title><dc:creator>Mahmoud Reza Pourkarim, Samad Amini-Bavil-Olyaee, Philippe Lemey, Piet Maes, Marc Van Ranst</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.015</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-15</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-15</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000144/abstract?rss=yes"><title>Human adenoviruses in respiratory infections: Sequencing of the hexon hypervariable region reveals high sequence variability - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000144/abstract?rss=yes</link><description>Abstract: Background: In respiratory infections, human adenoviruses (hAdV) of species B1 and C are frequently detected, but severe or even fatal disease outbreaks are predominantly caused by only few serotypes. The molecular typing of hAdV hexon sequences can help to speed up the discrimination of serotypes, thus improving on-time epidemiological examinations and patient care.Objectives: We aimed to develop a molecular method for the rapid species B1 and C serotype identification in respiratory samples based on sequence generation of the hexon hypervariable region (HVR).Study design: We developed two PCR-based genotyping systems for a generic HVR amplification and sequence determination of species B1 and C viruses. The assays were applied to hAdV prototypes and 106 samples.Results: The primer sets proved to be capable of amplifying all B1 and C serotypes. The viruses detected in clinical samples belong to serotypes 1, 2, 3, 5 and 6. The obtained sequences of serotypes 2, 3 and 5 form 2–3 phylogenetic clusters that are based on the characteristic amino acid changes within the variable HVR sites.Conclusions: Our assay can significantly speed up the time-span needed for serotype identification and will improve epidemiological surveillance and patient care. The obtained hexon sequences of field viruses vary significantly and form multiple genetic lineages. The variability is focussed on the HVR sites and can be interpreted as the ongoing evolutionary process. Further research is needed on the hexon sequence variability of other (respiratory) hAdV serotypes.</description><dc:title>Human adenoviruses in respiratory infections: Sequencing of the hexon hypervariable region reveals high sequence variability - Corrected Proof</dc:title><dc:creator>Barbara Biere, Brunhilde Schweiger</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.005</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-11</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-11</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000193/abstract?rss=yes"><title>The effectiveness of routine laboratory findings in determining disease severity in patients with Crimean-Congo hemorrhagic fever: Severity prediction criteria - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000193/abstract?rss=yes</link><description>Abstract: Background: Crimean-Congo hemorrhagic fever (CCHF) is a potentially fatal disease caused by a tick-borne virus from the Bunyaviridae family.Objectives: To determine the predictive criteria for severity among patients with CCHF based on clinical and laboratory findings.Study design: This retrospective study was conducted on patients with CCHF and hospitalized between June 2004 and August 2008 at Karadeniz Technical University, Turkey. Demographic characteristics, clinical findings and laboratory tests on admission of all patients with CCHF were investigated.Results: A total of 152 patients with confirmed CCHF were investigated. Sixty-three (41.4%) of these patients were in the severe group. Laboratory findings using the ROC curve method and optimum diagnostic cut-off points for specific laboratory parameters in the severe group were; PLT: 90,000, Hb: 13.5g/dL, PT: 13.1s, aPTT: 34s, INR: 1, AST: 117U/L, ALT: 71U/L, AST/ALT: 1.62, LDH: 508U/L, CK: 267U/L and CRP: 0.59mg/dL. At multivariable analysis, the risk for a severe clinical course in CCHF patients increased 2.59 and 3.93 times in the presence of platelet count and Hb below cut-off values, whereas the same risk increased 2.95, 2.92 and 3.47 times when the results for INR, AST and CRP, respectively, were above the predetermined cut-off values.Conclusions: A number of laboratory findings that can easily be measured at routine examination of patients hospitalized with a suspicion of CCHF are valuable and sensitive predictors. These parameters will contribute considerably to the design, practice and management of supportive treatment, blood and blood products replacement and intensive care services.</description><dc:title>The effectiveness of routine laboratory findings in determining disease severity in patients with Crimean-Congo hemorrhagic fever: Severity prediction criteria - Corrected Proof</dc:title><dc:creator>Gurdal Yilmaz, Iftihar Koksal, Murat Topbas, Hulya Yilmaz, Firdevs Aksoy</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.010</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-10</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-10</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000132/abstract?rss=yes"><title>Identification of G8 rotavirus strains determined as G12 by rotavirus genotyping PCR: Updating the current genotyping methods - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000132/abstract?rss=yes</link><description>Abstract: Background: Rotaviruses are classified into G- and P-types, which are determined by the reactivity with antibodies to the outer viral proteins, VP7 and VP4, respectively, or sequence variation in the genes encoding these proteins. There are presently a number of different rotavirus strains co-circulating within the UK, with the common human strains G1P[8], G2P[4] and G9P[8] being the most prevalent. As part of strain surveillance for the European Rotavirus Network (EuroRotaNet) a cluster (n=29) of G8 strains was detected in the UK between February and May 2009.Objectives: G8 strains were initially mistyped as G12 through multiplex RT-PCR, therefore further investigation was performed to ascertain the reasons behind this mistyping.Study design: The genes encoding the VP7 of these G8 strains were sequenced and aligned with the existing G8- and G12-specific oligonucleotide primers.Results: Multiple alignment of sequences derived from these strains and the G8- and G12-specific oligonucleotide primers revealed a series of point mutations which resulted in mismatches at the 3′ end of the G8-specific primer binding site that prevented amplification with the G8-specific primer, whilst a close homology with the G12-specific primer allowed mis-priming. Both the G8 and G12 primers were redesigned and their ability to correctly identify G8 and G12 strains was evaluated and confirmed.Conclusion: These findings highlight the importance of monitoring the specificity and sensitivity of the genotyping methods in order to detect changes in the genotype distribution and changes associated with genetic drift of common or uncommon genotypes.</description><dc:title>Identification of G8 rotavirus strains determined as G12 by rotavirus genotyping PCR: Updating the current genotyping methods - Corrected Proof</dc:title><dc:creator>Farah Aladin, Sameena Nawaz, Miren Iturriza-Gómara, Jim Gray</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.004</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-08</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-08</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS138665321000017X/abstract?rss=yes"><title>Viral load assay sensitivity and low level viremia in HAART treated HIV patients - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS138665321000017X/abstract?rss=yes</link><description>Abstract: Background: The recent introduction of highly sensitive viral load assays resulted in a significant increase in number of treated HIV-infected patients with a detectable viral load. The significance of a viral load between 20 and 50copies/mL remains unclear.Objectives: To compare the performance of three viral load assays, with special attention for specificity and sensitivity at the lowest level of quantification.Study design: Samples (n=181) were selected from 62 HIV-positive individuals that experience viral blips or episodes of low but detectable viremia under antiretroviral treatment, and from 216 HIV-negative individuals. Each sample was tested in at least two of three assays: the Cobas Amplicor HIV-1 Monitor (CAP/CA), the Cobas Ampliprep/Cobas TaqMan HIV-1 version 1 (CAP/CTM1) and the Cobas Ampliprep/Cobas TaqMan HIV-1 version 2 (CAP/CTM2).Results: No false positive results were recorded. Kappa statistics revealed fair to moderate agreement between the results of the three assays, but important differences in sensitivity were observed, with the highest sensitivity reported for CAP/CTM2 followed by CAP/CTM1 and CAP/CA. The differences in sensitivity remained after equalization of the detection limit for all assays at 50copies/mL. Analysis of samples collected over time showed that patients with single blips in CAP/CA present with recurrent blips in CAP/CTM1 and persistent detectable viremia in CAP/CTM2.Conclusions: Viral load results between 20 and 50copies/mL in either CAP/CTM1 or CAP/CTM2, indicate true viremia. The availability of highly sensitive assays force reconsideration of the terms ‘undetectable’ viral load and ‘virological success’ of antiretroviral treatment.</description><dc:title>Viral load assay sensitivity and low level viremia in HAART treated HIV patients - Corrected Proof</dc:title><dc:creator>Chris Verhofstede, Filip Van Wanzeele, Jacqueline Reynaerts, Marianne Mangelschots, Jean Plum, Katrien Fransen</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.008</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-08</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-08</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000181/abstract?rss=yes"><title>Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000181/abstract?rss=yes</link><description>Abstract: Background: Drug-resistant cytomegalovirus (CMV) infections can cause significant morbidity among high-risk transplant recipients.Objectives: The aims of this study were to determine the incidence and clinical consequences of CMV mutations conferring ganciclovir resistance in pediatric solid organ transplant (SOT) patients who received valganciclovir oral solution or tablets for prophylaxis of CMV disease. Recombinant CMV mutants were also generated to assess the role of two UL97 mutations of unknown significance.Study design: Genotypic resistance mutations and CMV viral load were sought in blood samples from pediatric SOT recipients who received valganciclovir prophylaxis for 100 days. Recombinant viruses containing novel CMV UL97 mutations were generated using a bacterial artificial chromosome containing the CMV genome to assess ganciclovir susceptibility.Results: Overall, four known resistance UL97 mutations were observed in blood samples from 2 of 46 patients during the study with no development of CMV disease. Two UL97 changes (M615V and V466G) of unknown significance and one UL97 mutation (C603R) associated with ganciclovir resistance, but not yet confirmed by marker transfer, were also detected. Recombinant viruses containing these novel mutations were generated to assess ganciclovir susceptibility. The M615V recombinant virus was susceptible to ganciclovir while the V466G and C603R mutant viruses displayed 3.5-fold and 3.6-fold decreases in susceptibility, respectively.Conclusions: The low incidence of ganciclovir resistance-associated mutations and the absence of clinical consequences associated with drug-resistant viruses observed in this pilot study should encourage the design of larger clinical trials aimed at evaluating the efficacy of valganciclovir prophylaxis and treatment in the pediatric setting.</description><dc:title>Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis - Corrected Proof</dc:title><dc:creator>Mélanie Martin, Nathalie Goyette, Jane Ives, Guy Boivin</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.009</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-08</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-08</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000028/abstract?rss=yes"><title>Phylogenetic analysis of human P[8]G9 rotavirus strains circulating in Brazil reveals the presence of a novel genetic variant - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000028/abstract?rss=yes</link><description>Abstract: Background: Group A rotavirus (RV-A) genotype P[8]G9 has emerged as one of the leading causes of gastroenteritis in children worldwide and currently is recognized as one of the five most common genotypes detected in humans. High intragenotype diversity in G9 RV-A has been observed, and nowadays, based on the genetic variability of the VP7 gene, six different phylogenetic lineages and eleven sublineages were described.Objectives: To study the degree of genetic variation and evolution of Brazilian P[8]G9 RV-A strains.Study design: Phylogenetic analysis of 19 P[8]G9 RV-A strains isolated from 2004 to 2007 in five different Brazilian states was conducted using the NSP1, NSP3, NSP5, VP4 and VP7 genes. For the VP4 and VP7 genes, 3D protein structure predictions were generated to analyze the spatial distribution of amino acid substitutions observed in Brazilian strains.Results: Based on the phylogenetic analyses, all Brazilian strains clustered within lineage G9-III and P[8]-3 for VP7 and VP4, respectively, and were classified as genotype A1, T1 and H1 for the NSP1, NSP3 and NSP5 genes, respectively. Interestingly, all the strains isolated in Acre State (Northern Brazil) formed a closely related cluster clearly separated from the other Brazilian and prototype strains with regard to the five genes studied. Unique amino acid substitutions were observed in Acre strains in comparison with the prototype and Brazilian strains.Conclusion: Inclusion of Acre strains in the phylogenetic analysis revealed the presence of a novel genetic variant and demonstrated a diversification of P[8]G9 rotaviruses in Brazil.</description><dc:title>Phylogenetic analysis of human P[8]G9 rotavirus strains circulating in Brazil reveals the presence of a novel genetic variant - Corrected Proof</dc:title><dc:creator>Luis Fernando López Tort, Eduardo de Mello Volotão, Marcos César Lima de Mendonça, Marcelle Figueira Marques da Silva, Alessandra A. Siqueira, Rosane Maria Santos Assis, Gonzalo Moratorio, Juan Cristina, José Paulo G. Leite</dc:creator><dc:identifier>10.1016/j.jcv.2009.12.018</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-05</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-05</prism:publicationDate></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653210000168/abstract?rss=yes"><title>Relative lymphopenia and monocytosis may be considered as a surrogate marker of pandemic influenza a (H1N1) - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653210000168/abstract?rss=yes</link><description>A novel influenza A (H1N1) [pandemic influenza A (PI)] virus has spread rapidly across the globe. In March and April 2009, an outbreak of respiratory illness was first noted in Mexico, which was eventually identified as being related to PI. The outbreak disseminated rapidly to the other countries. Turkey is among the mostly affected countries.</description><dc:title>Relative lymphopenia and monocytosis may be considered as a surrogate marker of pandemic influenza a (H1N1) - Corrected Proof</dc:title><dc:creator>Ömer Coşkun, Ismail Yasar Avci, Kenan Sener, Halil Yaman, Recai Ogur, Hurrem Bodur, Can Polat Eyigün</dc:creator><dc:identifier>10.1016/j.jcv.2010.01.007</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-02-04</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-02-04</prism:publicationDate><prism:section>LETTER TO THE EDITOR</prism:section></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653209005952/abstract?rss=yes"><title>Human polyoma viruses and disease with emphasis on clinical BK and JC - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653209005952/abstract?rss=yes</link><description>Abstract: Polyoma viruses are ubiquitous infecting many different mammalian species including humans. There are five known human polyoma viruses. JC virus and BK virus are two polyoma viruses identified nearly three decades ago. Recently WU, KI and Merkel cell polyoma viruses have been isolated from humans. The exact role of these three newly discovered viruses in human disease is not known. Most human polyoma disease is caused by BK and JC viruses which are usually acquired in childhood. Approximately 50–80% of humans have seropositivity to these viruses. Clinically apparent diseases in immunocompetent hosts are extremely rare. These viruses remain latent possibly in the lymphoid organs, neuronal tissue, and kidney and under the circumstances of severe immunosuppression both these viruses reactivate. Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate. BK virus is urotheliotropic and its reactivation causes a form of interstitial nephritis, known as BK or polyoma virus associated nephropathy which is associated with high graft loss if not recognized early. There are no known effective antiviral agents for any of the polyoma viruses.</description><dc:title>Human polyoma viruses and disease with emphasis on clinical BK and JC - Corrected Proof</dc:title><dc:creator>Raghavender Boothpur, Daniel C. Brennan</dc:creator><dc:identifier>10.1016/j.jcv.2009.12.006</dc:identifier><dc:source>Journal of Clinical Virology (2010)</dc:source><dc:date>2010-01-08</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2010-01-08</prism:publicationDate><prism:section>REVIEW</prism:section></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653209005460/abstract?rss=yes"><title>Febrile illness in a returned traveller from Thailand - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653209005460/abstract?rss=yes</link><description>A previously healthy female in her fifties, returned from Phuket, Thailand after a 3-week holiday stay. She was an experienced traveller with multiple earlier journeys to the south-east Asia. On day 3 after returning home to Norway, she fell ill and contacted her primary health care physician by telephone complaining over headache, myalgia, joint pain, vomiting and fever of 38.7°C. Over the next days she experienced transient improvement, although high-peeking fever reaching 39°C persisted. On day 7 she once more phoned her physician and was advised to stay home in town, instead of spending the weekend at her cabin as planned. She went anyway.</description><dc:title>Febrile illness in a returned traveller from Thailand - Corrected Proof</dc:title><dc:creator>Bjørn Waagsbø, Anders Sundøy, Liv Ragnhild Høyvoll</dc:creator><dc:identifier>10.1016/j.jcv.2009.11.005</dc:identifier><dc:source>Journal of Clinical Virology (2009)</dc:source><dc:date>2009-12-09</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2009-12-09</prism:publicationDate><prism:section>VIROLOGY QUESTION AND ANSWER SCHEME (VIROQAS)</prism:section></item><item rdf:about="http://www.journalofclinicalvirology.com/article/PIIS1386653209002315/abstract?rss=yes"><title>WITHDRAWN: Viral Hepatitis: global goals for vaccination - Corrected Proof</title><link>http://www.journalofclinicalvirology.com/article/PIIS1386653209002315/abstract?rss=yes</link><description>This article has been withdrawn at the request of the author. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.</description><dc:title>WITHDRAWN: Viral Hepatitis: global goals for vaccination - Corrected Proof</dc:title><dc:creator>Daniel Lavanchy</dc:creator><dc:identifier>10.1016/j.jcv.2009.05.028</dc:identifier><dc:source>Journal of Clinical Virology (2009)</dc:source><dc:date>2009-07-06</dc:date><prism:publicationName>Journal of Clinical Virology</prism:publicationName><prism:publicationDate>2009-07-06</prism:publicationDate></item></rdf:RDF>